Supplementary Figure 1. Nomogram of FDX1 and clinical parameters for predicting prognosis of glioma patients.

Supplementary Figure 2. KEGG pathway analysis for differentially expressed genes between high- and low-FDX1 expression groups.

Supplementary Figure 3. Immune status comparison among different tumor types (**A**, **B**) Comparisons of immune status in LGG. (**C**, **D**) Comparisons of immune status in GBM. (**E**, **F**) Correlation of FDX1 with plasma cells and T cells CD4 memory activated in LGG. (**G**, **H**) Correlation of FDX1 with T cells and T cells CD4 memory activated in GBM.

Supplementary Figure 4. Correlation of FDX1 methylation level with clinical prognosis.